Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des résultats du traitement antidépresseur à l’aide des scores de risque polygéniques : Rapport sur l’étude CAN-BIND-1
The Canadian Journal of Psychiatry · 2025-07 · 70 (7) · 552-564
DOI: 10.1177/07067437251329073 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Canadian Journal of Psychiatry, online erschienen am 29.03.2025. Verfasst von Leen Magarbeh und 24 weiteren Autor:innen. Beteiligte Einrichtung: Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Major Depressive Disorder, Multifactorial Inheritance, Antidepressive Agents, Aripiprazole. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ontario Brain Institute, Canadian Institutes of Health Research, Servier Canada.
Abstract (Originalsprache)
Objective
The genetic architecture of antidepressant response is poorly understood. This study investigated whether polygenic risk scores (PRSs) for major psychiatric disorders and a personality trait (neuroticism) are associated with antidepressant treatment outcomes.
Methods
We analysed 148 participants with major depressive disorder (MDD) from the Canadian Biomarker Integration Network for Depression-1 (CAN-BIND-1) cohort. Participants initially received escitalopram (ESC) monotherapy for 8 weeks. Nonresponders at week 8 received augmentation with aripiprazole (ARI), while responders continued ESC until week 16. Primary outcomes were remission status and symptom improvement measured at weeks 8 and 16. At week 16, post-hoc stratified analyses were performed by treatment arm (ESC-only vs. ESC + ARI). Eleven PRSs derived from genome-wide association studies of psychiatric disorders (e.g., MDD and post-traumatic stress syndrome (PTSD)) and neuroticism, were analysed for associations with these outcomes using logistic and linear regression models.
Results
At week 8, a higher PRS for PTSD was nominally associated with a lower probability of remission (odds ratio (OR) = 0.08 [0.014–0.42], empirical p -value = 0.017) and reduced symptom improvement (beta (standard error) = −29.15 (9.76), empirical p -value = 0.019). Similarly, a higher PRS for MDD was nominally associated with decreased remission probability (OR = 0.38 [0.18–0.78], empirical p -value = 0.044). However, none of the results survived multiple testing corrections. At week 16, the stratified analysis for the ESC-only group revealed that a higher PRS for MDD was associated with increased remission probability (empirical p- value = 0.034) and greater symptom improvement (empirical p -value = 0.02). In contrast, higher PRSs for schizophrenia (empirical p -value = 0.013) and attention-deficit hyperactivity disorder (empirical p -value = 0.032) were associated with lower symptom improvement. No significant associations were observed in the ESC + ARI group.
Conclusions
These findings suggest that PRSs may influence treatment outcomes, particularly in ESC monotherapy. Replication in larger studies is needed to validate these observations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
- Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada.
- Center for Translational and Computational Neuroimmunology, Columbia University Medical Center, New York, USA.
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
- Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
- Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.
ORCID-Profile: Leen Magarbeh, Samar S M Elsheikh, Farhana Islam, Emytis Tavakoli, Stefan Kloiber, Benicio N Frey, Roumen Milev, Sagar V Parikh, Stefanie Hassel, Rudolf Uher, Raymond W Lam, Jane A Foster, Sidney H Kennedy, Daniel J Müller
Förderung
- Ontario Brain Institute
- Canadian Institutes of Health Research
- Servier Canada
- Lundbeck Canada
Zitieren
APA
Magarbeh, L., Elsheikh, S. S. M., Islam, F., Marshe, V. S., Men, X., Tavakoli, E., Kronenbuerger, M., Kloiber, S., Frey, B. N., Milev, R., Soares, C. N., Parikh, S. V., Placenza, F., Hassel, S., Taylor, V. H., Leri, F., Blier, P., Uher, R., Farzan, F., …, & Müller, D. J. (2025). Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des résultats du traitement antidépresseur à l’aide des scores de risque polygéniques : Rapport sur l’étude CAN-BIND-1. The Canadian Journal of Psychiatry, 70(7), 552-564. https://doi.org/10.1177/07067437251329073
Vancouver
Magarbeh L, Elsheikh SSM, Islam F, Marshe VS, Men X, Tavakoli E, et al. Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des résultats du traitement antidépresseur à l’aide des scores de risque polygéniques : Rapport sur l’étude CAN-BIND-1. The Canadian Journal of Psychiatry. 2025;70(7):552-564. doi:10.1177/07067437251329073
BibTeX
@article{Magarbeh2025,
author = {Magarbeh, Leen and Elsheikh, Samar S M and Islam, Farhana and Marshe, Victoria S and Men, Xiaoyu and Tavakoli, Emytis and Kronenbuerger, Martin and Kloiber, Stefan and Frey, Benicio N and Milev, Roumen and Soares, Claudio N and Parikh, Sagar V and Placenza, Franca and Hassel, Stefanie and Taylor, Valerie H and Leri, Francesco and Blier, Pierre and Uher, Rudolf and Farzan, Faranak and Lam, Raymond W and Turecki, Gustavo and Foster, Jane A and Rotzinger, Susan and Kennedy, Sidney H and Müller, Daniel J},
title = {Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des résultats du traitement antidépresseur à l’aide des scores de risque polygéniques : Rapport sur l’étude CAN-BIND-1},
journal = {The Canadian Journal of Psychiatry},
year = {2025},
volume = {70},
number = {7},
pages = {552--564},
doi = {10.1177/07067437251329073}
}
EUVIMED